Argos Therapeutics (ARGS) Stock Price Up 11%

Argos Therapeutics Inc (NASDAQ:ARGS) shares rose 11% during mid-day trading on Wednesday . The company traded as high as $2.70 and last traded at $2.42. Approximately 1,012,300 shares traded hands during mid-day trading, an increase of 148% from the average daily volume of 407,553 shares. The stock had previously closed at $2.18.

The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.

Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.00) earnings per share (EPS) for the quarter.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new position in Argos Therapeutics Inc (NASDAQ:ARGS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 18.33% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Argos Therapeutics (ARGS) Stock Price Up 11%” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/01/26/argos-therapeutics-args-stock-price-up-11.html.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit